| 前列腺癌分子靶向治疗的研究进展 |
| |
| 引用本文： | 彭旭辉,罗红梅,汪翼.前列腺癌分子靶向治疗的研究进展[J].南华大学学报(医学版),2021(2):235-238. |
| |
| 作者姓名： | 彭旭辉 罗红梅 汪翼 |
| |
| 作者单位： | 南华大学附属第二医院泌尿外科一区,湖南省衡阳市 421001;南华大学衡阳医学院应用解剖与 生殖医学研究所 组织学与胚胎学教研室,湖南省衡阳市 421001 |
| |
| 摘 要： | 前列腺癌(PCa)是全球第二大男性肿瘤,中国PCa发病率呈逐年增长的趋势；晚期前列腺癌激素抵抗力的难治性及治疗药物的不良反应给患者带来严重的伤害。分子靶向治疗(MTT)能精确抑制肿瘤生长,具有降低不良反应的特性,是未来治疗前列腺癌的方向。本文对前列腺癌肿瘤细胞靶向治疗、肿瘤血管靶向治疗和免疫调节靶向治疗等分子靶向治疗研究进展进行了综述。
|
| 关 键 词： | 前列腺癌 分子靶向治疗 免疫检查点 [ |
Research progress of molecular targeted therapy for prostate cancer |
| |
| PENG Xuhui,LUO Hongmei,WANG Yi.Research progress of molecular targeted therapy for prostate cancer[J].Journal of Nanhua University(Medical Edition),2021(2):235-238. |
| |
| Authors: | PENG Xuhui LUO Hongmei WANG Yi |
| |
| Institution: | The First Department of Urology, the Second Affiliated Hospital, University of South China, Hengyang, Hunan 421001, China;Clinical Anatomy & Reproductive Medicine Application Institute, Hengyang Medical College, Department of Histology and Embryology, University of South China, Hengyang, Hunan 421001, China |
| |
| Abstract: | Prostate cancer(PCa) is the second largest male tumor in the world. The incidence rate in China is increasing year by year. The refractory and refractory side effects of advanced prostate cancer cause serious harm to patients. Molecular targeted therapy(MTT) has the characteristics of precisely inhibiting tumor growth and reducing adverse reactions, which is the future direction of prostate cancer treatment. This paper reviewed the research progress of molecular targeted therapy of prostate cancer, including prostate cancer cell targeted therapy, tumor vascular targeted therapy and immunomodulatory targeted therapy. |
| |
| Keywords: | prostate cancer molecular targeted therapy immune checkpoint |
|
| 点击此处可从《南华大学学报(医学版)》浏览原始摘要信息 |
| 点击此处可从《南华大学学报(医学版)》下载免费的PDF全文 |
|
